Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 38Colorectal Neoplasms 18Small Cell Lung Carcinoma 8Neoplasms 8Stomach Neoplasms 7Neoplasm Metastasis 5Biliary Tract Neoplasms 5Sarcoma, Ewing 4Rhabdomyosarcoma 4Recurrence 4Osteosarcoma 4Rectal Neoplasms 3Ovarian Neoplasms 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Solid Tumor 2Neuroblastoma 2Nasopharyngeal Carcinoma 2Metastatic Pancreatic Adenocarcinoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Wilms Tumor 1Weight Loss 1Somatostatinoma 1Solid Tumor Cancer 1Small Cell Lung Cancer Extensive Stage 1

Interventions

irinotecan sucrosofate 1camrelizumab 1Radiotherapy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Cancer Patients × irinotecan sucrosofate × Clear all
NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
44 enrolled
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡